Lyra Therapeutics, Inc. Sample Contracts
LYRA THERAPEUTICS, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 27th, 2020 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofAS”), Jefferies LLC (“Jefferies”) and William Blair & Company, L.L.C. (“William Blair”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofAS, Jefferies and William Blair are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [●] additional shares of Common Stock. The afo
LYRA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • April 27th, 2020 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ______________, 20[20] between Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
LYRA THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Amended and Restated Controlled Equity OfferingSM Sales AgreementSales Agreement • March 22nd, 2024 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and Cantor Fitzgerald & Co. (the “Agent”), are parties to that certain Sales Agreement dated September 1, 2023 (the “Original Agreement”). The Company and the Agent desire to amend and restate the Original Agreement in its entirety as set forth in this Amended and Restated Sales Agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 11th, 2021 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
Employment AgreementEmployment Agreement • March 29th, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of February 2, 2023, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and John Bishop (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 27th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2025, between Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT LYRA THERAPEUTICS, INC.Common Stock Purchase Warrant • June 27th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the 24-month anniversary of the date that the Commission declares the registration statement covering the resale of the Warrant Shares effective (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LYRA THERAPEUTICS, INC.Pre-Funded Common Stock Purchase Warrant • June 27th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) to subscribe for and purchase from Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 12th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2025, between Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Employment AgreementEmployment Agreement • November 9th, 2021 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of September 13, 2021, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Jason Cavalier (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN LYRA THERAPEUTICS, INC. AND JASON CAVALIEREmployment Agreement • August 12th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Amendment (the “Amendment”) to that certain Employment Agreement between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Jason Cavalier (the “Executive”) dated as of September 13, 2021 (the “Employment Agreement”) is made as of this 7th day of March, 2025 (the “Amendment Date”), by and among the Company and the Executive.
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential. LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • August 9th, 2021 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), entered into as of May 31, 2021 (the “Effective Date”), is entered into by and among LianBio Inflammatory Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Lian”) LianBio, a corporation organized under the laws of the Cayman Islands (“LianBio”) (for purposes of Sections 2.9(a) (By Lian) and 14.17 (LianBio Guarantee)) and Lyra Therapeutics, Inc., a Delaware corporation (“Lyra”).
LYRA THERAPEUTICS, INC. EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 6th, 2020 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
This Agreement dated as of January 10, 2020 is entered into by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), Carmichael Roberts, George Whitesides and Robert Langer (individually, a “Founder” and collectively, the “Founders”) and the individuals and entities listed as preferred stockholders on Schedule A attached hereto (individually, an “Investor” and collectively, the “Investors”).
SUBLEASESublease Agreement • March 22nd, 2024 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of December 21, 2023 and is made by and between RVAC MEDICINES (US), INC., a Delaware corporation (“Sublessor”), and LYRA THERAPEUTICS, INC., a Delaware corporation (“Sublessee”) with both jointly referred to as the “Parties”.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 13th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of April 7, 2022 by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors identified on Exhibit A attached thereto (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN LYRA THERAPEUTICS, INC. AND MARIA PALASISEmployment Agreement • August 12th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Amendment (the “Amendment”) to that certain Employment Agreement between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Maria Palasis (the “Executive”) dated as of April 27, 2020 and as amended as of February 16, 2022 (the “Employment Agreement”) is made as of this 7th day of March, 2025 (the “Amendment Date”), by and among the Company and the Executive.
Transition AgreementTransition Agreement • November 9th, 2021 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Transition Agreement (“Agreement”) is made by and between Don Elsey (“Executive”) and Lyra Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of September 12, 2021 (the “Agreement Date”), effective as of the Effective Date (as defined below).
Employment AgreementEmployment Agreement • April 27th, 2020 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of April 27, 2020, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Don Elsey (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
ContractLease Agreement • March 29th, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
bxP Boston Properties Prudential Center 800 Boylston StreetBoston, MA 02199-8103 www.bostonproperties.com Boston Properties, Inc.(NYSE:BXP)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 8th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), entered into as of September 26, 2022 (the “Amendment Effective Date”), is entered into by and between LianBio Inflammatory Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Lian”), and Lyra Therapeutics, Inc., a Delaware corporation, a Delaware corporation (“Lyra”). Lian and Lyra are each referred to herein individually as a “Party”, and collectively as the “Parties.”
SEVENTH AMENDMENT TO LEASELease Agreement • July 14th, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Seventh Amendment to Lease (the “Seventh Amendment”) is made as of July 12, 2023, by and between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and LYRA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SIXTH AMENDMENT TO LEASELease Agreement • November 16th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Sixth Amendment to Lease (the “Sixth Amendment”) is made as of November 14, 2022, by and between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and LYRA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 13th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 7, 2022 by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), the Share Investors identified on Exhibit A attached hereto (each a “Share Investor” and collectively the “Share Investors”) and the Warrant Investors identified on Exhibit B attached hereto (each a “Warrant Investor” and collectively the “Warrant Investors”, and together with the Share Investors, each an “Investor” and collectively the “Investors”).
LYRA THERAPEUTICS, INC. NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 13th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
This Agreement dated as of April 7, 2022 is entered into by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”) and the individuals and entities listed as investors on Schedule A attached hereto (individually, an “Investor” and collectively, the “Investors”).
LYRA THERAPEUTICS, INC. AMENDMENT NO. 1 TO NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 31st, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
This Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement, dated as of May 25, 2023 (this “Amendment”) is entered into by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned Investors party to the Ninth Amended and Restated Investor Rights Agreement, dated as of April 7, 2022 (the “Rights Agreement”), by and among the Company and the Investors party thereto. Capitalized terms used by not defined herein shall have the meanings ascribed to such terms in the Rights Agreement, as amended by this Amendment.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 31st, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 25, 2023 by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors identified on Exhibit A attached thereto (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
NOVATION AGREEMENTNovation Agreement • March 13th, 2025 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
THIS NOVATION AGREEMENT (this “Novation Agreement”) is made and entered into as of November 15, 2024 (the “Novation Effective Date”) by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Development (HK) Limited (as successor-in-interest to LianBio Inflammatory Limited), a private company limited by shares organized under the laws of Hong Kong (“LianBio Development”), and Lyra Therapeutics, Inc., a Delaware corporation (“Lyra”). Each of LianBio, LianBio Development and Lyra is referred to herein as a “Party” and, collectively, as the “Parties”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 31st, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 25, 2023 by and among Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
Separation Agreement and ReleaseSeparation Agreement • August 5th, 2020 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Separation Agreement and Release ( this “Release”) is made by and between Laura Edgerly-Pflug (“Executive”) and Lyra Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Release shall have the meanings set forth in the Employment Agreement (as defined below).